Stuart J. Schnitt

Stuart J. Schnitt, M.D.
Chief of Breast Oncologic Pathology, Dana-Farber/Brigham and Women's Cancer Center; Associate Director of the Dana-Farber Cancer Institute/Brigham and Women's Hospital Breast Oncology Progra,
Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
sschnitt@bwh.harvard.edu

Stuart J. Schnitt, M.D.,is Chief of Breast Oncologic Pathology at the Dana-Farber/Brigham and Women's Cancer Center and Associate Director of the Dana-Farber Cancer Institute/Brigham and Women's Hospital Breast Oncology Program and Harvard Medical School.  

He was the Director of the Division of Anatomic Pathology at Beth Israel Deaconess Medical Center, co-leader of the Dana Farber Harvard Cancer Center Breast Program, a Professor of Pathology at Harvard Medical School and an internationally recognized expert in breast pathology. He did his internship and residency in Anatomic and Clinical Pathology at Beth Israel Hospital in Boston followed by a fellowship in surgical pathology, also at Beth Israel Hospital.

Dr. Schnitt has published over 300 original articles, review articles, editorials, commentaries, and book chapters, primarily in the area of breast diseases. He has authored a popular breast pathology textbook entitled “Biopsy Interpretation of the Breast”, now in its second edition; this book has also been published in Chinese. In addition, he is one of the editors of the 4th Edition of the “World Health Organization Classification of Tumours of the Breast”, published in 2012. He has been cited in multiple editions of “The Best Doctors in America” and “America’s Top Doctors”.

Dr. Schnitt is a Past President of the United States and Canadian Academy of Pathology (2010-2011). He has lectured extensively around the world. His research interests and contributions to our understanding of benign breast diseases and breast cancer have been broad, but have largely focused on risk factors for local recurrence in patients with invasive breast cancer and ductal carcinoma in situ treated with breast conserving therapy, benign breast disease and breast cancer risk, and stromal-epithelial interactions in breast tumor progression.